vs
Cytek Biosciences, Inc.（CTKB）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是帕可Bio的1.4倍（$62.1M vs $44.6M）。Cytek Biosciences, Inc.净利率更高（-70.9% vs -90.4%，领先19.5%）。帕可Bio同比增速更快（13.8% vs 8.1%）。Cytek Biosciences, Inc.自由现金流更多（$-1.8M vs $-19.9M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs 7.3%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
CTKB vs PACB — 直观对比
营收规模更大
CTKB
是对方的1.4倍
$44.6M
营收增速更快
PACB
高出5.7%
8.1%
净利率更高
CTKB
高出19.5%
-90.4%
自由现金流更多
CTKB
多$18.2M
$-19.9M
两年增速更快
CTKB
近两年复合增速
7.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $44.6M |
| 净利润 | $-44.1M | $-40.4M |
| 毛利率 | 52.9% | 37.1% |
| 营业利润率 | -9.0% | -92.3% |
| 净利率 | -70.9% | -90.4% |
| 营收同比 | 8.1% | 13.8% |
| 净利润同比 | -557.1% | -1802.7% |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBPACB
| Q4 25 | $62.1M | $44.6M | ||
| Q3 25 | $52.3M | $38.4M | ||
| Q2 25 | $45.6M | $39.8M | ||
| Q1 25 | $41.5M | $37.2M | ||
| Q4 24 | $57.5M | $39.2M | ||
| Q3 24 | $51.5M | $40.0M | ||
| Q2 24 | $46.6M | $36.0M | ||
| Q1 24 | $44.9M | $38.8M |
净利润CTKBPACB
| Q4 25 | $-44.1M | $-40.4M | ||
| Q3 25 | $-5.5M | $-38.0M | ||
| Q2 25 | $-5.6M | $-41.9M | ||
| Q1 25 | $-11.4M | $-426.1M | ||
| Q4 24 | $9.6M | $2.4M | ||
| Q3 24 | $941.0K | $-60.7M | ||
| Q2 24 | $-10.4M | $-173.3M | ||
| Q1 24 | $-6.2M | $-78.2M |
毛利率CTKBPACB
| Q4 25 | 52.9% | 37.1% | ||
| Q3 25 | 52.7% | 41.4% | ||
| Q2 25 | 52.3% | 36.9% | ||
| Q1 25 | 48.6% | -3.7% | ||
| Q4 24 | 58.5% | 25.6% | ||
| Q3 24 | 56.3% | 25.0% | ||
| Q2 24 | 54.6% | 16.5% | ||
| Q1 24 | 51.3% | 29.1% |
营业利润率CTKBPACB
| Q4 25 | -9.0% | -92.3% | ||
| Q3 25 | -17.6% | -101.1% | ||
| Q2 25 | -23.3% | -112.8% | ||
| Q1 25 | -36.1% | -1154.5% | ||
| Q4 24 | 5.2% | -390.1% | ||
| Q3 24 | -8.2% | -160.3% | ||
| Q2 24 | -18.3% | -488.3% | ||
| Q1 24 | -23.9% | -209.6% |
净利率CTKBPACB
| Q4 25 | -70.9% | -90.4% | ||
| Q3 25 | -10.5% | -98.9% | ||
| Q2 25 | -12.2% | -105.4% | ||
| Q1 25 | -27.5% | -1146.8% | ||
| Q4 24 | 16.8% | 6.0% | ||
| Q3 24 | 1.8% | -151.9% | ||
| Q2 24 | -22.4% | -481.3% | ||
| Q1 24 | -13.8% | -201.4% |
每股收益（稀释后）CTKBPACB
| Q4 25 | — | $-0.11 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-1.44 | ||
| Q4 24 | — | $-0.44 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.64 | ||
| Q1 24 | — | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $279.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $341.7M | $5.3M |
| 总资产 | $461.5M | $784.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTKBPACB
| Q4 25 | $90.9M | $279.5M | ||
| Q3 25 | $93.3M | $298.7M | ||
| Q2 25 | $75.5M | $314.7M | ||
| Q1 25 | $95.3M | $343.1M | ||
| Q4 24 | $98.7M | $389.9M | ||
| Q3 24 | $162.3M | $471.1M | ||
| Q2 24 | $177.9M | $509.8M | ||
| Q1 24 | $168.8M | $561.9M |
股东权益CTKBPACB
| Q4 25 | $341.7M | $5.3M | ||
| Q3 25 | $378.6M | $36.1M | ||
| Q2 25 | $377.6M | $61.5M | ||
| Q1 25 | $379.6M | $91.6M | ||
| Q4 24 | $395.7M | $506.6M | ||
| Q3 24 | $385.5M | $453.1M | ||
| Q2 24 | $389.1M | $492.7M | ||
| Q1 24 | $392.6M | $649.0M |
总资产CTKBPACB
| Q4 25 | $461.5M | $784.1M | ||
| Q3 25 | $494.9M | $803.2M | ||
| Q2 25 | $493.3M | $825.5M | ||
| Q1 25 | $482.6M | $860.8M | ||
| Q4 24 | $499.5M | $1.3B | ||
| Q3 24 | $491.2M | $1.5B | ||
| Q2 24 | $483.7M | $1.5B | ||
| Q1 24 | $492.1M | $1.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-19.9M |
| 自由现金流率自由现金流/营收 | -2.9% | -44.6% |
| 资本支出强度资本支出/营收 | 1.6% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流CTKBPACB
| Q4 25 | $-771.0K | $-19.1M | ||
| Q3 25 | $-3.9M | $-18.7M | ||
| Q2 25 | $108.0K | $-29.4M | ||
| Q1 25 | $-125.0K | $-44.1M | ||
| Q4 24 | $2.0M | $-30.6M | ||
| Q3 24 | $13.2M | $-45.5M | ||
| Q2 24 | $6.2M | $-54.3M | ||
| Q1 24 | $4.0M | $-75.7M |
自由现金流CTKBPACB
| Q4 25 | $-1.8M | $-19.9M | ||
| Q3 25 | $-4.6M | $-18.8M | ||
| Q2 25 | $-1.5M | $-29.9M | ||
| Q1 25 | $-974.0K | $-45.4M | ||
| Q4 24 | $1.1M | $-32.3M | ||
| Q3 24 | $12.2M | $-46.3M | ||
| Q2 24 | $5.2M | $-55.7M | ||
| Q1 24 | $3.4M | $-79.6M |
自由现金流率CTKBPACB
| Q4 25 | -2.9% | -44.6% | ||
| Q3 25 | -8.7% | -48.9% | ||
| Q2 25 | -3.2% | -75.3% | ||
| Q1 25 | -2.3% | -122.3% | ||
| Q4 24 | 1.9% | -82.3% | ||
| Q3 24 | 23.7% | -115.7% | ||
| Q2 24 | 11.0% | -154.8% | ||
| Q1 24 | 7.6% | -205.0% |
资本支出强度CTKBPACB
| Q4 25 | 1.6% | 1.9% | ||
| Q3 25 | 1.3% | 0.2% | ||
| Q2 25 | 3.5% | 1.4% | ||
| Q1 25 | 2.0% | 3.7% | ||
| Q4 24 | 1.6% | 4.1% | ||
| Q3 24 | 2.0% | 2.0% | ||
| Q2 24 | 2.3% | 4.1% | ||
| Q1 24 | 1.3% | 10.0% |
现金转化率CTKBPACB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | -12.93× | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
